Sugi Predict

Sugi Predict / Targets / NPC1

NPC1

NPC intracellular cholesterol transporter 1 · O15118 · NPC1 on Sugi Atlas →

3,188,964 patent compounds predicted against NPC1, 1,655,491 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3777 SCHEMBL3777 0.37 10/20
Paclitaxel Paclitaxel (SCHEMBL3976) 1.00 8/20
Docetaxel Anhydrous Docetaxel Anhydrous (SCHEMBL4417) 1.00 8/20
Docetaxel Anhydrous Docetaxel Anhydrous (SCHEMBL4418) 1.00 8/20
Docetaxel Anhydrous Docetaxel Anhydrous (SCHEMBL4419) 1.00 8/20
Paclitaxel Paclitaxel (SCHEMBL9240) 0.97 8/20
SCHEMBL3979 SCHEMBL3979 0.70 8/20
SCHEMBL1672 SCHEMBL1672 0.51 8/20
SCHEMBL9394 SCHEMBL9394 0.49 8/20
SCHEMBL8211 SCHEMBL8211 0.56 7/20
SCHEMBL4746 SCHEMBL4746 0.50 7/20
SCHEMBL8475 SCHEMBL8475 0.45 7/20
Dipyridyl Dipyridyl (SCHEMBL5922) 0.78 6/20
Isoflavone Isoflavone (SCHEMBL8028) 0.66 6/20
SCHEMBL4792 SCHEMBL4792 0.64 6/20
SCHEMBL9769 SCHEMBL9769 0.59 6/20
SCHEMBL7158 SCHEMBL7158 0.54 6/20
SCHEMBL3925 SCHEMBL3925 0.53 6/20
SCHEMBL4805 SCHEMBL4805 0.52 6/20
SCHEMBL8602 SCHEMBL8602 0.51 6/20

Clinical trials — most relevant to NPC1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of Miglustat in Chinese NPC Patients PHASE4COMPLETED
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons PHASE4COMPLETED
Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) PHASE4UNKNOWN
Effect of Evolocumab on Vascular Function PHASE4COMPLETED
Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets Study PHASE4COMPLETED
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis PHASE4RECRUITING
The Low HDL On Six Weeks Statin Therapy (LOW) Study PHASE4UNKNOWN
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) PHASE3COMPLETED
Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 PHASE1/PHASE2COMPLETED
Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients PHASE1/PHASE2COMPLETED
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine PHASE1/PHASE2COMPLETED
Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C PHASE1/PHASE2COMPLETED
Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer PHASE1/PHASE2COMPLETED
The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease. PHASE2RECRUITING
Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease PHASE1COMPLETED
Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1) PHASE1COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
Study of Inborn Errors of Cholesterol Synthesis and Related Disorders nanCOMPLETED
Induced Pluripotent Stem Cells for Niemann Pick Disease nanCOMPLETED
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C nanRECRUITING
Biomarker for Niemann Pick Type C Disease (BioNPC) nanWITHDRAWN
Longitudinal Study of Cognition With Niemann-Pick Disease, Type C nanCOMPLETED
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health nanUNKNOWN
Plant Stanols and Gene Expression Profile nanCOMPLETED
Effect of Simvastatin and Ezetimibe on Lipid and Inflammation nanCOMPLETED
Early Access Program With Arimoclomol in US Patients With NPC nanAVAILABLE
Normal Pressure Hydrocephalus Biomarkers Investigation nanUNKNOWN
Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques nanUNKNOWN
HIV Reverse Cholesterol Transport Study nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NPC1 binder may also engage these)

ProteinNameSimilarity
P56941 — 1.000 P56941 →
O35604 — 1.000 O35604 →
Q12200 — 0.995 Q12200 →
Q19127 — 0.994 Q19127 →
Q9VRC9 — 0.990 Q9VRC9 →
Q6T3U3 — 0.986 Q6T3U3 →
H2L0G5 — 0.986 H2L0G5 →
Q61086 — 0.984 Q61086 →
Q6T3U4 — 0.984 Q6T3U4 →
Q0WMJ8 — 0.984 Q0WMJ8 →
A8XKF2 — 0.984 A8XKF2 →
Q9W5D4 — 0.984 Q9W5D4 →
B2RFN2 — 0.984 B2RFN2 →
O88917 — 0.983 O88917 →
Q09630 — 0.983 Q09630 →
P16065 — 0.983 P16065 →
Q8W469 — 0.983 Q8W469 →
Q8JZZ7 — 0.983 Q8JZZ7 →
P34389 — 0.983 P34389 →
B4NBB0 — 0.983 B4NBB0 →
ERMP1 Endoplasmic reticulum metallopeptidase 1 0.983 landscape →
Q84K47 — 0.983 Q84K47 →
Q0DWA9 — 0.983 Q0DWA9 →
B4JG39 — 0.983 B4JG39 →
Q9C100 — 0.982 Q9C100 →
F1Q8R9 — 0.982 F1Q8R9 →
G4YM00 — 0.982 G4YM00 →
Q8CF82 — 0.982 Q8CF82 →
Q9GLC3 — 0.982 Q9GLC3 →
Q8MSU3 — 0.982 Q8MSU3 →